OMERS ADMINISTRATION Corp purchased a new stake in CVS Health Corporation (NYSE:CVS – Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 74,907 shares of the pharmacy operator’s stock, valued at approximately $7,749,000.
Several other hedge funds also recently added to or reduced their stakes in the stock. Leigh Baldwin & CO. LLC acquired a new position in shares of CVS Health in the 2nd quarter valued at about $830,000. Osmosis Investment Management UK Ltd acquired a new stake in CVS Health during the second quarter worth about $6,979,000. Sanctuary Advisors LLC acquired a new position in CVS Health in the second quarter valued at approximately $18,769,000. Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of CVS Health during the second quarter valued at approximately $120,995,000. Finally, Meiji Yasuda Asset Management Co Ltd. bought a new stake in shares of CVS Health in the 2nd quarter worth approximately $3,155,000. 80.66% of the stock is owned by institutional investors and hedge funds.
CVS Health Trading Up 1.1%
CVS Health stock opened at $94.06 on Tuesday. The firm has a 50 day simple moving average of $101.88 and a 200-day simple moving average of $89.08. The company has a debt-to-equity ratio of 0.74, a current ratio of 0.87 and a quick ratio of 0.66. The stock has a market capitalization of $120.31 billion, a PE ratio of 24.88, a price-to-earnings-growth ratio of 0.85 and a beta of 0.61. CVS Health Corporation has a 12-month low of $69.51 and a 12-month high of $110.68.
CVS Health Dividend Announcement
The company also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 23rd were issued a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date of this dividend was Thursday, July 23rd. CVS Health’s payout ratio is presently 70.37%.
Wall Street Analysts Forecast Growth
CVS has been the topic of a number of recent research reports. UBS Group raised their target price on CVS Health from $122.00 to $126.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Mizuho lifted their price objective on shares of CVS Health from $110.00 to $115.00 and gave the company an “outperform” rating in a research report on Monday, June 8th. JPMorgan Chase & Co. upped their target price on shares of CVS Health from $111.00 to $118.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 12th. Barclays raised their price target on shares of CVS Health from $106.00 to $108.00 and gave the company an “overweight” rating in a research note on Thursday, August 6th. Finally, Bank of America increased their price objective on CVS Health from $100.00 to $110.00 and gave the stock a “buy” rating in a report on Monday, June 22nd. Twenty-two investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, CVS Health has a consensus rating of “Moderate Buy” and an average price target of $107.17.
CVS Health Profile
CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.
Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.
See Also
- Five stocks we like better than CVS Health
- Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters
- Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain
- Snowflake Could Be Headed for New Highs Despite Insider Selling
- MongoDB Is Surging—And the Next Catalyst Is Almost Here
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.
